The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

A first-of-its-kind study testing an mRNA vaccine for norovirus, the highly contagious winter vomiting bug, is launching in the UK and around the world. Norovirus, which causes vomiting and diarrhoea, ...

Experts hope the Moderna jab could stop people developing the vomiting and diarrhoea bug, which is linked to around 12,000 ...

A groundbreaking vaccine for norovirus, the notorious winter vomiting bug, is set to enter final-stage trials in the UK ...

Social media users are spreading new levels of misinformation based on discredited claims that nanobots are lurking in ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...